Odonate Therapeutics, Inc. (ODTC)
OTCMKTS: ODTC · Delayed Price · USD
1.48
0.00 (0.00%)
Jun 24, 2022 4:00 PM - Market closed
Company Description
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer.
The company was founded in 2013 and is based in New York, New York.
Odonate Therapeutics, Inc.
| Country | United States |
| Founded | 2013 |
| IPO Date | Dec 7, 2017 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 137 |
Contact Details
Address:
4747 Executive Dr San Diego, California 92121-3095 United States | |
| Phone | 332 206 0935 |
| Website | odonate.com |
Stock Details
| Ticker Symbol | ODTC |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001717452 |
Key Executives
| Name | Position |
|---|---|
| Kevin C. Tang | Chairman and Chief Executive Officer |
| Michael S. Hearne | Chief Financial Officer and Principal Accounting Officer |
| Ryan Cole | Senior Vice President of Operations |
| Dr. Steven S. Pfeiffer Ph.D. | Senior Vice President of Technical Operations |
| Thomas Wei | Chief Scientific Officer |
| Stewart M. Kroll | Chief Development Officer |
| Tracey McKennon | Senior Vice President of Quality Assurance |
| Jennifer Schroeder | Senior Vice President of Program Management and Technology |
| Kim Ma | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Feb 10, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2022 | 15-12B | Securities registration termination [Section 12(b)] |
| Jan 31, 2022 | EFFECT | Notice of Effectiveness |
| Jan 31, 2022 | EFFECT | Notice of Effectiveness |
| Jan 31, 2022 | EFFECT | Notice of Effectiveness |
| Jan 28, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Jan 28, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2022 | POS AM | Post-Effective amendments for registration statement |